Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: ALX4, an epigenetically down regulated tumor suppressor, inhibits breast cancer progression by interfering Wnt/β-catenin pathway

Fig. 8

High expression of ALX4 predicts a longer survival time in breast cancer patients. a 142 breast cancer patients were divided into two groups according to the expression of ALX4 by identified by IHC. Scale bar, 100 μm. b Kaplan-Meier survival analysis of ALX4 expression in breast cancer patients. Long OS was observed in the high ALX4 expression group compared with the low ALX4 group. c Multivariate Coxregression analysis of the relationship between ALX4 expression and OS of breast cancer patients. ALX4 was determined to be an independent favorable prognostic factor. d Kaplan-Meier survival analysis of ALX4 expression in breast cancer patients at clinical stage II + III. Long OS was observed in the high ALX4 expression group compared with the low ALX4 group. e Multivariate Coxregression analysis of the relationship between ALX4 expression and OS of breast cancer patients at clinical stage II + III. ALX4 was determined to be an independent favorable prognostic factor

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us